cortex pharmaceuticals造句
例句與造句
- In April 2007 Cortex Pharmaceuticals submitted two large data packages to the FDA regarding CX717.
- It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development.
- "' CX717 "'is an ampakine compound created by Christopher Marrs and Gary Rogers in 1996 at Cortex Pharmaceuticals.
- "' Org 26576 "'is an ampakine drug originally developed by Cortex Pharmaceuticals and then licensed to Organon International for development.
- These companies, as well as start-ups such as Cortex Pharmaceuticals, NeoTherapeutics and David Pharmaceuticals are competing with Memory Pharmaceuticals, Tracy said.
- It's difficult to find cortex pharmaceuticals in a sentence. 用cortex pharmaceuticals造句挺難的
- Cortex Pharmaceuticals Inc . rose 2 1 / 8 to 5 after the company said studies show that its Ampalex product induces changes in the function of neurons active in memory formation.
- He helped start a company called Cortex Pharmaceuticals to develop a class of drugs called Ampakines, which amplify the signals received by AMPA receptors and thus might function as memory enhancers.
- According to the Wikipedia article CX717 and borne out by at least early sources, somehow Cortex Pharmaceuticals has kept the actual structure of CX717 secret-" "'while " "'patenting it and referencing it extensively in several patent applications!
- According to a Cortex Pharmaceuticals press release, " Consistent with all previous studies involving over 220 patients and healthy adults, this study demonstrated that CX717 was safe, well tolerated, and produced no increase in heart rate, blood pressure or other cardiovascular side effects ".
- One data set went to the FDA's Division of Neurology Drug Products for the treatment of Alzheimer's disease, while the other went to the Division of Psychiatry Products where the company filed a second CX717 IND for the treatment of ADHD . According to a Cortex Pharmaceuticals press release, the submitted data package " provides clear evidence that the specific histopathological changes seen in animal toxicology studies, which previously caused the FDA to put CX717 on clinical hold, is a postmortem fixation artifact and is not found in the tissue of the animal when it is still living ".